_regulatory-considerations-for-drug-products-containing-nanomaterials-us-fda-perspective-preview-1.jpg "Regulatory Considerations for Drug Products Containing Nanomaterials: US FDA Perspective from dbnpa fda Video Screenshot Preview 1")
Gallery_regulatory-considerations-for-drug-products-containing-nanomaterials-us-fda-perspective-preview-3.jpg "Regulatory Considerations for Drug Products Containing Nanomaterials: US FDA Perspective from dbnpa fda Video Screenshot Preview 3")
Gallery_regulatory-considerations-for-drug-products-containing-nanomaterials-us-fda-perspective-preview-hqdefault.jpg "Regulatory Considerations for Drug Products Containing Nanomaterials: US FDA Perspective from dbnpa fda Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 14 minutes 10 seconds
👁 View: 127 times
Play Audio:👁 View: 127 times
Description:
TAUVOD
TAUVOD
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_ro39s-supply-tracker-helps-patients-locate-in-demand-glp-1-drugs-amid-shortages.webp "Telehealth company Ro launched a new online tracker to help patients find popular weight loss and diabetes drugs called GLP-1s. These drugs have faced shortages in the US. Demand has outpaced manufacturers' ability to scale up production. Ro's Supply Tracker provides real-time data on drug availability, dose size, and pharmacy location to help more people access treatments. Notifications help users find pharmacies with supplies and request prescription transfers. The data may also help the FDA keep shortage lists updated."){kind=tracking}
_what-the-fda39s-approval-of-aducanumab-might-mean-for-a-booming-clinical-research-industry.webp "Dan Sfera")
⏲ 7 minutes 15 seconds 👁 95
_fda-nanoday-symposium-2022-welcome-keynote-and-session-1.webp "U.S. Food and Drug Administration")
_about-fdas-biomarker-qualification-program.webp "U.S. Food and Drug Administration")
_fda-nanoday-symposium-2022-session-2.webp "U.S. Food and Drug Administration")
_fda-pulls-infant-formula-from-shelves-due-to-lack-of-evaluation.webp "Crecelac and Farmalac-branded infant formula is being recalled after being placed on shelves without proper evaluation by the Food and Drug Administration. According to the FDA, the products \")
_petrie-flom-center-124-assessing-the-viability-of-fdas-biosimilar-pathway.webp "Harvard Law School")
⏲ 1 hour 24 minutes 3 seconds 👁 150
_ro39s-supply-tracker-helps-patients-locate-in-demand-glp-1-drugs-amid-shortages.jpg){kind=tracking}
_what-the-fda39s-approval-of-aducanumab-might-mean-for-a-booming-clinical-research-industry.jpg)
_fda-nanoday-symposium-2022-welcome-keynote-and-session-1.jpg)
_about-fdas-biomarker-qualification-program.jpg)
_fda-nanoday-symposium-2022-session-2.jpg)
_fda-pulls-infant-formula-from-shelves-due-to-lack-of-evaluation.jpg)
_petrie-flom-center-124-assessing-the-viability-of-fdas-biosimilar-pathway.jpg)
![[+]](/images/menu.gif){kind=small}